Drugs / Army Liposomal Formulation QS21
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04784767 Background | Apr 2021 → Mar 2023 | COVID-19 | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Army Liposomal Formulation QS21 | “Army Liposomal Formulation QS21 (ALFQ)” NCT04784767 ↗ |
| Known as | ALFQ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04784767 ↗ |
| Modality | Other / unclassified | “an experimental adjuvant called ALFQ” NCT04784767 ↗ |
| Route | Intramuscular | “receive 25 μg or 50 μg of SpFN/ALFQ or saline placebo intramuscularly” PMID 38761816 ↗ May 2024 |